Reassessment of Fracture Risk in women after 3 years of treatment with Zoledronic Acid: when is it reasonable to discontinue treatment?

Conclusions: After 3 years of ZOL, in women who have a TH T-score above -2.5, no recent incident fracture and no more than one risk factor (almost 55% of the population), risk for subsequent fracture is low if treatment is discontinued (for MorphVertFx average risk 3.2%, range 2.8-3.8% for subgroups, and for NVF average risk 5.8%, range 1.1-8.8% for subgroups). In these patients, discontinuation for up to 3 years is reasonable.
PMID: 25215556 [PubMed - as supplied by publisher]

Source: The Journal of Clinical Endocrinology and Metabolism - September 12, 2014 Category: Endocrinology Authors: Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, Cummings SR, Black DM Tags: J Clin Endocrinol Metab Source Type: research